© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction
Department of Internal Medicine, Academic Medical Center, Suite F4-222, Meibergdreef 9, 1105 AZ, The Netherlands
* Tel.: +31-20-566-5990, fax: +31-20-566-9158 y.m.smulders{at}amc.uva.nl
Acute massive pulmonary embolism has a high mortality rate. Fatal haemodynamic deterioration is caused by an acute increase in pulmonary vascular resistance. Traditionally, the degree of mechanical obstruction of the pulmonary vasculature by the embolic thrombus is considered to be the major determinant of this increase in right ventricular afterload. However, there is evidence to suggest that another factor plays an important role, since there is a marked discrepancy between the haemodynamic manifestations of acute pulmonary embolism and the degree of mechanical obstruction. Historic studies indicate that this discrepancy is largely explained by pulmonary vasoconstriction caused by vasoactive mediators, released mainly by activated platelets. Thromboxane-A2 and serotonin are probably the two most important pulmonary vasoconstrictors in this context. Antagonising their effects dramatically increases tolerance to experimental pulmonary embolism in animals. In humans, this concept should eventually find its way into clinical practice. In the future, acute massive pulmonary embolism could be treated with antagonists to pulmonary vasoconstrictors, or with direct pulmonary vasodilators.
KEYWORDS COX, cyclooxygenase; NO, nitric oxide; PAP, pulmonary artery pressure; PE, pulmonary embolism; PG, prostaglandin; PVR, pulmonary vascular resistance; TxA2, thromboxane-A2
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF] |
||||
![]() |
J. Krebs, S. J. Ferguson, S. P. Hoerstrup, B. G. Goss, A. Haeberli, and N. Aebli Influence of Bone Marrow Fat Embolism on Coagulation Activation in an Ovine Model of Vertebroplasty J. Bone Joint Surg. Am., February 1, 2008; 90(2): 349 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ghaye, A. Ghuysen, V. Willems, B. Lambermont, P. Gerard, V. D'Orio, P. A. Gevenois, and R. F. Dondelinger Severe Pulmonary Embolism:Pulmonary Artery Clot Load Scores and Cardiovascular Parameters as Predictors of Mortality Radiology, June 1, 2006; 239(3): 884 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ghaye, A. Ghuysen, P.-J. Bruyere, V. D'Orio, and R. F. Dondelinger Can CT Pulmonary Angiography Allow Assessment of Severity and Prognosis in Patients Presenting with Pulmonary Embolism? What the Radiologist Needs to Know RadioGraphics, January 1, 2006; 26(1): 23 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Souza-Costa, T. Zerbini, A. C. Palei, R. F. Gerlach, and J. E. Tanus-Santos L-arginine Attenuates Acute Pulmonary Embolism-Induced Increases in Lung Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Chest, November 1, 2005; 128(5): 3705 - 3710. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C.T. Palei, R. A.G. Zaneti, G. M. Fortuna, R. F. Gerlach, and J. E. Tanus-Santos Hemodynamic Benefits of Matrix Metalloproteinase-9 Inhibition by Doxycycline During Experimental Acute Pulmonary Embolism Angiology, September 1, 2005; 56(5): 611 - 617. [Abstract] [PDF] |
||||
![]() |
C. A. Dias-Junior, D. C. Souza-Costa, T. Zerbini, J. B. T. da Rocha, R. F. Gerlach, and J. E. Tanus-Santos The Effect of Sildenafil on Pulmonary Embolism-Induced Oxidative Stress and Pulmonary Hypertension Anesth. Analg., July 1, 2005; 101(1): 115 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ghuysen, B. Lambermont, J.-M. Dogne, P. Kolh, V. Tchana-Sato, P. Morimont, D. Magis, J. Hanson, P. Segers, and V. D'Orio Effect of BM-573 [N-Terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 964 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Morris, J. J. Marsh, P. G. Chiles, C. A. Pedersen, R. G. Konopka, A. C. Gamst, and O. Loza Embolization itself stimulates thrombus propagation in pulmonary embolism Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H818 - H822. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Kreit The Impact of Right Ventricular Dysfunction on the Prognosis and Therapy of Normotensive Patients With Pulmonary Embolism Chest, April 1, 2004; 125(4): 1539 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stratmann and G. A. Gregory Neurogenic and Humoral Vasoconstriction in Acute Pulmonary Thromboembolism Anesth. Analg., August 1, 2003; 97(2): 341 - 354. [Full Text] [PDF] |
||||
![]() |
A. E. Jones, J. A. Watts, J. P. Debelak, L. R. Thornton, J. G. Younger, and J. A. Kline Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L1072 - L1081. [Abstract] [Full Text] [PDF] |
||||









